Emergent BioSolutions Inc. (EBS)
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic
$8.17
+1.68%
Mkt Cap $414.70M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 26, 2026 | $217.50M | $148.70M | -31.63% | $0.11 | -$0.43 | -490.91% | — | — |
| Q4 2025 Oct 29, 2025 | $217.50M | $231.10M | +6.25% | -$0.12 | $1.06 | +983.33% | — | — |
| Q3 2025 Aug 6, 2025 | $203.67M | $140.90M | -30.82% | -$0.26 | $0.16 | +161.54% | — | — |
| Q2 2025 May 7, 2025 | $219.00M | $222.20M | +1.46% | $0.49 | $0.71 | +44.90% | — | — |
| Q1 2025 Mar 3, 2025 | $279.00M | $189.30M | -32.15% | -$0.35 | $0.05 | +114.29% | — | — |
| Q4 2024 Nov 6, 2024 | $259.00M | $293.80M | +13.44% | $0.49 | $1.37 | +179.59% | — | — |
| Q3 2024 Aug 6, 2024 | $190.00M | $254.70M | +34.05% | -$0.97 | -$2.32 | -139.18% | — | — |
| Q2 2024 May 1, 2024 | $190.00M | $300.40M | +58.11% | -$0.86 | $0.59 | +168.60% | — | — |
| Q1 2024 Mar 6, 2024 | $293.53M | $276.60M | -5.77% | -$0.33 | -$0.77 | -133.33% | — | — |
| Q4 2023 Dec 11, 2023 | — | $270.50M | — | -$0.12 | -$1.44 | -1100.00% | — | — |
| Q3 2023 Aug 8, 2023 | $216.17M | $337.90M | +56.31% | -$0.98 | -$5.15 | -425.90% | — | — |
| Q2 2023 May 9, 2023 | $143.28M | $165.10M | +15.23% | -$1.67 | -$3.17 | -89.82% | — | — |
| Q1 2023 Feb 27, 2023 | — | $330.70M | — | — | -$1.76 | — | — | — |
| Q4 2022 Nov 8, 2022 | $268.30M | $240.00M | -10.55% | -$0.06 | -$1.27 | -2016.67% | — | — |
| Q3 2022 Aug 1, 2022 | $270.94M | $242.70M | -10.42% | $0.63 | -$0.86 | -236.51% | — | — |
| Q2 2022 Apr 28, 2022 | $283.57M | $307.50M | +8.44% | $0.24 | -$0.07 | -130.41% | — | — |
| Q1 2022 Feb 24, 2022 | $669.04M | $723.20M | +8.09% | $4.27 | $4.50 | +5.39% | — | — |
| Q4 2021 Nov 4, 2021 | $628.69M | $329.00M | -47.67% | $2.03 | -$0.65 | -132.02% | — | — |
| Q3 2021 Jul 29, 2021 | $397.50M | $397.50M | +0.00% | $1.81 | $0.33 | -81.77% | — | — |
| Q2 2021 Apr 29, 2021 | $374.10M | $343.00M | -8.31% | $1.12 | $1.53 | +36.61% | — | — |